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SHORT ABSTRACT (120 words) 
Recently, there has been interest in lysergic acid diethylamide (LSD) and psilocybin for depression, 
anxiety and fear of death in terminal illness. The aim of this review is to discuss the potential use of 
LSD and psilocybin for patients with persistent pain. Lysergic acid diethylamide and psilocybin are 5-
hydroxytryptamine receptor agonists and may interact with nociceptive and anti-nociceptive 
processing. Tentative evidence from a systematic review suggests that LSD (7 studies, 323 
participants) and psilocybin (3 studies, 92 participants) may be beneficial for depression and anxiety 
associated with distress in life-threatening diseases. Lysergic acid diethylamide and psilocybin are 
generally safe if administered by a health care professional, although further investigations are 
needed to assess their utility for patients with persistent pain, especially associated with terminal 
illness.  





Chronic pain is a global health care problem and management using mainstay analgesic drugs has 
proven problematic. Recently, positive outcomes of small scale randomised controlled clinical trials 
has reawakened interest in the use of psychedelics for depression and anxiety related to fear of 
death in terminal illness. The aim of this review is to discuss the potential use of lysergic acid 
diethylamide (LSD) and psilocybin for patients with persistent pain. Research evidence suggests that 
LSD and psilocybin interact with physiological processes associated with pain, providing a scientific 
rationale for analgesic effects. Lysergic acid diethylamide and the active ingredient of psilocybin 
(psilocin) are 5-hydroxytryptamine (5-HT) receptor agonists with a high affinity for 5-HT2 receptors. 
5-hydroxytryptamine acts in the spinal cord and brainstem to inhibit onward transmission of 
nociceptive information and 5-HT acts in the cerebrum to influence emotional, motivational, and 
cognitive appraisal systems involved in pain perception. Lysergic acid diethylamide and psilocybin 
influence processing in the default mode network in the brain.  Pain disrupts activity in the default 
mode network, and therefore LSD and psilocybin may alleviate adverse intrusive cognitions and 
reverse the breakdown of the normal self. Tentative evidence from a systematic review suggests 
that LSD (7 studies, 323 participants) and psilocybin (3 studies, 92 participants) may be beneficial for 
depression and anxiety associated with distress in life-threatening diseases. However, there is an 
absence of clinical trials on the efficacy of LSD and psilocybin for pain per se.  LSD and psilocybin are 
generally safe if administered under the supervision of a health care professional. Our review 
suggests there is a need for further investigation of derivatives of LSD and psilocybin to determine 
their suitability for patients with persistent pain, especially associated with terminal illness, in the 
presence and absence of neuropsychiatric ailments. 
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There is an age-old tradition of using fungi and plants to produce psychedelic effects in religious 
ceremonies and ritual healing. Isolation of substances from fungi and plants led to the development 
of a range of psychedelic drugs including lysergic acid diethylamide (LSD, made from ergotamine, 
found in the fungus ergot), psilocybin (found in Psilocybe mushrooms), dimethyltryptamine (found in 
various trees and shrubs including Acacia species, Mimosa tenuiflora, and Psychotria viridis) and 
mescaline (found in the peyote cactus Lophophora williamsii). Psychedelic drugs (classical 
hallucinogens) cause visual, auditory, tactile and olfactory hallucinations and/or an altered sense of 
reality through perceptual anomalies of sensation, cognition, and affect. Drugs that produce a sense 
of detachment from the surrounding environment and/or a state of delirium (e.g. ketamine, 
dextromethorphan, phencyclidine, nitrous oxide, belladonna) may also produce hallucinations 
and/or perceptual anomalies. However, these drugs are not considered psychedelic hallucinogens in 
the ‘classical’ sense.  
 
Originally, psychedelic drugs were used to assist explorations of ‘inner experience’ during 
psychotherapy. Clinical research in the 1950s and 1960s suggested that psychedelic drugs were of 
therapeutic promise for distress secondary to terminal cancer and for addiction [1]. However, 
medical use declined due to prohibition resulting from their use as recreational drugs as part of the 
counter culture [2]. Recently, there has been a resurgence of interest in the therapeutic use of 
psychedelic drugs in neuropsychiatry due to positive outcomes of small scale randomised controlled 
clinical trials [3-6]. This has prompted calls for serious consideration of psychedelics such as LSD and 
psilocybin as viable treatment for depression and anxiety related to fear of death in terminal illness 
[1, 7, 8]. In the United Kingdom, LSD and psilocybin are currently classified as schedule one drugs 
under the Misuse of Drugs Regulations 2001 [9].  
 
To date, the use of psychedelic drugs for the management of pain and associated symptoms has 
received little attention. The aim of this review was to evaluate the potential use of lysergic acid 
diethylamide (LSD) and psilocybin for patients with persistent pain. 
 
Lysergic acid diethylamide (LSD) 
Pharmacology 
In 1938, the Swiss chemist Albert Hofmann was trying to synthesize a respiratory and circulatory 
stimulant from ergotamine, a chemical from the fungus ergot (Claviceps purpurea)[2]. Hoffman 




produced a series of lysergic acid derivatives and named the twenty-fifth compound lysergic acid 
diethylamide-25 (LSD-25). Hoffman abandoned testing with LSD-25 because it caused restlessness in 
the experimental animals. In 1943, Hoffman synthesized LSD-25 again and found that it produced 
psychedelic experiences when self-administered. Sandoz distributed LSD under the trade-name 
Delysid as an investigational drug for psychiatric research and a commercial medication for LSD-
assisted psychotherapy for the treatment of alcoholism, neurosis, and psychosomatic disorders. In 
the 1950s, the Central Intelligence Agency in the United States explored the use of LSD for mind 
control and chemical warfare. Increasing recreational use and its influence on youth culture in the 
1960s led to the prohibition of LSD in the United States. Consequently, global psychedelic research 
became dormant for several decades. 
 
Lysergic acid diethylamide is 9,10-didehydro-N,N-diethyl-6-methylergoline-8β-carboxamide (IUPAC 
name) with a molecular formula of C20H25N3O  (non-proprietary name is lysergide) [10]. The 
abbreviation LSD was derived from the German name LysergSäureDiethylamid. Lysergic acid 
diethylamide is part of a family of indole alkyl amines that includes other psychedelic substances 
with substituted tryptamines such as N,N-dimethyltryptamine (DMT) and psilocin. Lysergic acid 
diethylamide is a 5-hydroxytryptamine (5-HT, serotonin) receptor agonist that passes through the 
blood brain barrier. Lysergic acid diethylamide has a high affinity for 5-HT2A and 5-HT2C receptor 
subtypes. Functionally, 5-HT2 receptors are G-protein coupled, with 5-HT2A and 5-HT2C subtypes 
having a widespread distribution in the central nervous system and involved in the regulation of 
mood, anxiety, cognition, psychosis, sleep-wakefulness and eating.  
 
Recently, findings from human studies have demonstrated the importance of 5-HT2A receptors in 
eliciting psychedelic effects. The 5-HT2A receptor antagonist Ketanserin blocks LSD-induced 
hypnogenic changes in various states of consciousness including dreaming, cognitive bizarreness, 
attributing relevance to meaningless stimuli, primary process thinking in imagery and emotionality, 
connectedness, meaningfulness and tracking of tonal structure in music [11-14]. Imaging studies 
suggest that 5-HT2A agonists produce acute psychedelic experiences via excitation of regions of the 
brain involved in emotion, cognition, memory and self-awareness including the medial and lateral 
frontal cortex and the medial temporal lobe [15]. 5-HT2A agonists also inhibit activity in the default 
mode network which is a collection of brain regions active during wakeful rest when an individual’s 
mind is not focused on the outside world but thinking about themselves, others, the past, or future 
(i.e. when the mind is ‘wandering’)[16].  





Therapeutic use  
The threshold dose of LSD to initiate psychedelic effects is between 20 and 30 μg p.o. (1-15 µg/kg 
body weight) with a moderate recreational dose typically 75-150 μg p.o. Physiological and 
psychological effects of LSD occur 30-45 minutes after ingestions and persist for 6 to 9 hours. There 
are no active metabolites following metabolism of LSD. Elimination is via the kidney. Plasma 
elimination half-life is 3 to 4 hours in man. Oral doses of LSD <100 μg produce vivid psychosensory 
effects, including increased sensory perception, illusionary changes of perceived objects, 
synesthesia, and enhanced mental imagery. Mood is intensified and thoughts accelerated and 
broadened in scope, including new associations and modified interpretation and meanings of 
relationships and objects. Typically, hypermnesia strengthens and ego weakens. The general state of 
consciousness can be compared to a daydream, but with pronounced affectivity and enhanced 
production of inner stimuli [17].  
 
The use of LSD in clinical practice requires expertise and patient cooperation because treatment 
response can be variable and unpredictable. LSD has been used to assist psychotherapy for a wide 
variety of psychiatric conditions, severe anxiety disorder (including existential distress in life-
threatening diseases), post-traumatic stress disorder, and drug dependencies (including tobacco and 
alcohol)[18-20]. When administered in structured therapeutic settings LSD can generate experiences 
that enhance self-realization which can alter an individual’s understanding of maladaptive cognitions 
and behaviours and promote an acceptance of behaviour change. LSD also enhances suggestibility 
that can enhance this effect. There has been renewed interest in the use of LSD (and psilocybin) to 
alleviate fear and distress associated with impending death in end-stage diseases for individuals who 
are refractory to conventional anxiolytics [21-23]. In this context, psychedelics are used to induce 
transcendental experiences that may offer insights, symbolism and meaning to dying including, for 
some people, comfort associated with an enhanced realization of continuity in an after-life [22-24]. 
Lysergic acid diethylamide has also been used by individuals to enhance creativity in art, literature 
and the sciences [25]. 
 
The safety profile of serotonergic psychedelics are good when administered in carefully controlled 
clinical settings. They have very low physiological toxicities, with no evidence of resulting organ 
damage or neuropsychological deficits even at very high doses [26-28]. Contra-indications are due to 
hazards resulting from hyperactivity and excitement and include individuals with cardiovascular 




disease, pregnancy, epilepsy, and psychosis. There is minimal physical dependence or compulsive 
drug-seeking behaviour when compared with other drugs of abuse such as cannabis, cocaine, 
methamphetamine, and opioids. There is no physical withdrawal syndrome but tolerance develops 
due to down-regulation of 5-HT receptors. There is cross-tolerance with other psychedelic agents 
including psilocybin and mescaline. Mortality rates with psychedelics are difficult to calculate as they 
are extremely rare (less than 1 in a million) (https://erowid.org/chemicals/lsd/lsd_death.shtml) with 
no reports of lethality directly associated with LSD, although acute delusional and paranoid states, 
prolonged psychosis, suicide, self-injury, fatal accidents and homicide have occurred whilst people 
are in LSD states. Adverse reactions include anxiety, paranoia, and delusions. Dysphoria (‘bad trips’) 
occur in approximately 20% of drug exposures during recreational use. A major concern are hazards 
due to potential erratic behaviour associated with the psychedelic experience. Safeguards against 
these risks include the exclusion of volunteers with personal or family history of psychotic disorders 
or other severe psychiatric disorders, establishing trust and rapport between session monitors and 
volunteer before the session, careful volunteer preparation, a safe physical session environment, 
and interpersonal support from at least two study monitors during the session [29]. Larsen reviewed 
case material in the Danish State Archives of 151 of 154 psychiatric patients treated with LSD in the 
1960s and subsequently received financial compensation in the 1980s for LSD-inflicted harm [30, 
31]. These patients experienced severe LSD-associated side effects that persisted for many years 
including flashbacks.  
 
Clinical Efficacy  
Clinical trials with small sample sizes provide initial evidence for efficacy of LSD for depression and 
anxiety related to terminal cancer and for addiction [32, 33]. A systematic review by Reiche et al. 
[34] of 11 clinical trials (445 participants) provided tentative evidence to support the use of LSD (7 
studies, 323 participants) and psilocybin (3 studies, 92 participants) to alleviate depression and 
anxiety associated with existential distress in life-threatening diseases. Side effects were minimal 
when there was adherence to safety guidelines [29]. Included in the review was a small randomized 
placebo-controlled crossover study by Gasser et al. [5] in which 12 patients with anxiety associated 
with life-threatening diseases received either high-dose LSD (200 µg) or low-dose LSD (20 µg) 
followed by an open-label crossover to 200 µg.  Reductions in trait anxiety were present at 2-month 
follow-up and sustained for 12-months post-treatment in 10 participants, with associated 
improvements in quality of life [35]. There were no prolonged adverse reactions. Krebs et al., [36] 




conducted a systematic review with meta-analysis of six trials (536 participants) and found that LSD 
(210–800 µg) reduced the likelihood of alcohol misuse compared with placebo. 
 
Psilocybin and psilocin 
Pharmacology  
Albert Hofmann also isolated psilocybin from the mushroom Psilocybe Mexicana (one of over 200 
species of psilocybin ‘magic mushrooms’).  Psilocybin is 4-phosphoryloxy-N,N-dimethyltryptamine 
(IUPAC name) with a molecular formula of C12H17N2O4P [10]. Psilocybin is a tryptamine alkaloid. 
When ingested orally is mostly dephosphorylated in the liver into the active agent psilocin, which 
has a half-life between one and three hours. Psilocybin and psilocin pass through the blood brain 
barrier. Psilocin is a full or partial agonist for 5-HT receptors with a high affinity for 5-HT2B and 5-
HT2C, and a lower affinity for 5-HT2A receptors. Actions via 5-HT2A and 5-HT2C receptors are similar to 
those described for LSD. 5-HT2B receptors are strongly expressed in the liver, kidney, heart and 
stomach but have a sparse distribution in the central nervous system were they are involved in the 
regulation of mood, anxiety, sleep-wakefulness and migraine. Psychedelic actions are via similar 
brain regions as LSD. Psilocybin decreases activity in the default mode network (e.g. posterior 
cingulate cortex and medial prefrontal cortex), the thalamus and the anterior cingulate cortex [37]. 
 
Therapeutic Use  
Psilocybin is approximately 100 times less potent than LSD. The threshold dose of psilocybin to 
initiate psychedelic effects is between 4 and 10 mg p.o. (50 and 300 µg/kg body weight) with 
recreational dosage typically between 10 and 50 mg p.o. (approximately 10–50 g fresh mushrooms, 
1-5 g dried mushrooms, plasma concentration approximately 8 µg/L). Physiological and 
psychological effects occur within 10 to 40 minutes and persist up to 6 hours depending on dose. A 
medium dosage of psilocybin (12–20 mg p.o.) may alter consciousness accompanied by heightened 
affect and introspection, and hypnagogic experiences that include illusions, synesthesia, and 
distortions in the sense of time.  Indications and clinical considerations for psilocybin are identical to 
those previously discussed for LSD including anxiety disorders, post-traumatic stress disorder, and 
drug dependency [18-20]. 
 
Adverse reactions following administration of psilocybin include hypertension, nausea, panic attacks 
and exacerbation of pre-existing psychosis. Eleven percent of respondents to an online survey study 
of 1993 recreational psilocybin users reported risk of physical harm to self or others during their 




worst ‘bad trip’ after consuming psilocybin mushrooms, with 2.7% reporting that they received 
medical attention [38]. Three participants reported the onset of enduring psychotic symptoms and 
three participants reported suicide attempts. There was a positive correlation between difficulty of 
experience and higher dose. Two large retrospective population studies, each over 130,000 U.S. 
adults, failed to find any evidence of lifetime use of serotonergic psychedelics and mental health 
problems [39, 40].  There was lower likelihood of inpatient mental health treatment and a reduced 
incidence of suicidal behaviour following use of psychedelics [39, 41]. Evidence from administration 
of carefully controlled doses of psilocybin in laboratory studies and clinical trials suggests that the 
incidence of psychological distress and/or risky behaviour is extremely low when there is careful 
screening, preparation, monitoring, drug-related adverse effects are managed at the time of drug 
administration and follow-up of participants occurs [1]. A small proportion of people are sensitive to 
psilocybin and a small proportion of people require high doses to achieve psychedelic effects. There 
are no known reports of direct lethality associated with psilocybin and no withdrawal syndrome 
following chronic use. Down-regulation of 5-HT receptors results in tolerance and cross-tolerance 
with mescaline and LSD.   
 
Clinical Efficacy  
The findings of clinical trials with small sample sizes provide tentative evidence for efficacy of 
psilocybin for depression and anxiety, alcohol and tobacco dependence, and obsessive-compulsive 
disorder. The systematic review by Reiche et al. [34] included three studies (92 participants) that 
suggested that psilocybin alleviates depression and anxiety associated with life-threatening diseases. 
Griffiths et al. [6] conducted a double blind randomised controlled crossover trial of 51 cancer 
patients with life-threatening diagnoses. They found that high-dose psilocybin (22 or 30 mg/70 kg) 
alleviated depressed mood and anxiety, and increased quality of life, life meaning, and optimism at 
6-month follow-up compared with very low dose (1 or 3 mg/70 kg). Ross et al. [42] conducted a 
double blind, placebo-controlled, crossover trial whereby 29 patients with cancer-related anxiety 
and depression received single-dose psilocybin (0.3 mg/kg) with psychotherapy or niacin (Vitamin 
B3) with psychotherapy. They found that psilocybin produced rapid, robust and enduring anxiolytic 
and anti-depressant effects that persisted to the 6.5-month follow-up in approximately 60-80% of 
participants with improved attitudes towards death. Grob et al. [24] found a reduction in anxiety 
relating to advanced stage cancer at 1 and 3 months after treatment with psilocybin and an 
improvement of mood that persisted for 6 months.  
 




Cahart-Harris et al. [43] conducted an open-label feasibility trial of 12 patients with moderate-to-
severe, unipolar, treatment-resistant major depression who received 10 mg p.o. psilocybin and 25 
mg p.o. seven days later in a supportive setting. The onset of psychedelic effects occurred within 30-
60 min after dosing, peaked at 2-3 hours and disappeared by 6 hours, with no serious, but some 
transient adverse effects (i.e. anxiety in all patients, confusion/thought disorders in nine patients, 
nausea in four patients, and headache in four patients). High-dose psilocybin improved depressive 
symptoms at 1 week and 3 months with sustained improvements in anxiety and anhedonia. Cahart-
Harris et al. [44] followed this up by reporting the findings of an open-label clinical trial of 19 
patients with treatment-resistant depression who had their functional brain activity measured using 
fMRI before and after psilocybin (10 mg followed by 25 mg, one-week apart). They found that the 
single high dose of psilocybin combined with psychotherapy to patients with treatment-resistant 
depression patients caused 100% improvement at 1 week and 47% at 5 weeks. 
 
There is very limited clinical trial data reviewing the use of psychedelics in the treatment of addiction. 
A meta-analysis of controlled trials has demonstrated a consistent and clinically significant beneficial 
effect of high-dose LSD [18]. Bogenschutz et al. [45] conducted an open label single-group study of 
ten alcohol-dependent participants who received one or two sessions of oral psilocybin in addition to 
motivational enhancement therapy. They found that abstinence increased for up to 36 weeks and that 
an increased psilocybin effect predicted decreases in drinking, craving and increases in abstinence self-
efficacy.  
 
Johnson et al. [46] conducted an open-label pilot study of 15 psychiatrically healthy nicotine-
dependent smokers who received moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of 
psilocybin within a structured 15-week smoking cessation treatment protocol and found that 12 
participants seven-day point prevalence abstinence at 6-month follow-up. The same investigators 
reported long-term follow-up data from this open-label pilot study and found that 10 participants 
were tobacco smoking abstinent at 12-month follow-up and nine participants were smoking 
abstinent at 16 months [47].  Moreno et al. [48] conducted a double-blind study in which nine 
participants with obsessive-compulsive disorder received increasing single-dose exposures of 
psilocybin with a one week washout (100 µg/kg), medium (200 μg/kg), and high (300 μg/kg) with an 
additional very low dose (25 μg/kg) administered randomly any time after the first dose. They found 
reductions in symptoms in all subjects in at least one of the testing sessions but there was no 
statistically significant effect of dose.  






Lysergic Acid Diethylamide, Psilocybin and Pain 
The pharmacological mechanism of action of psychedelics is complex and comprehensive review is 
beyond the scope of this article. Evidence suggests that LSD having an affinity for 5-HT, dopamine 
(D2) and trace amine-associated receptors (TAAR1). Psilocybin and psilocin have affinity for 5-HT 
receptors but not D2 receptors (see [49-51] for comprehensive reviews). Psychedelics may alleviate 
pain from actions producing psychedelic effects that indirectly affect an individual’s final experience 
of pain and/or actions with physiological systems directly involved in pain and its modulation.  
 
Psychedelic Experience and Pain  
The traditional view that pain is a faithful representation of activation of nociceptors and 
transmission through nociceptive pathways is outdated. Contemporary perspectives suggest that 
pain is a perceptual experience inferred from bodily sate (i.e., embodied) and socio-environmental 
context (i.e., embedded in the environment in which pain is experienced). An individual’s experience 
of pain is influenced by a wide variety of sensory, affective, cognitive, social, and bodily cues 
interpreted within current and evolutionary contexts [52-55]. Pain is defensive, promoting actions 
that attempt to reduce the impact of threat on the integrity of the body. Pain involves inferences 
associated with rationalizing complex, uncertain environments and is defined by the boundaries of 
actions available to the person. The ability to detect physiological state through interoceptive 
awareness diminishes when pain becomes chronic [56, 57].  
 
Psychedelic drugs produce acute psychedelic experiences by influencing activity in brain regions 
involved in processes that regulate emotion, cognition, memory and self-awareness. These brain 
regions are also associated with processes leading to perceptual experience of ‘embodied’ and 
‘embedded’ pain [15]. Brain imaging studies have found that the thalamus, anterior cingulate cortex, 
posterior insula and medial and lateral frontal cortices become active in response to transient 
noxious stimuli [58], although these regions also become active to non-noxious auditory, visual, 
mechanical and thermal stimuli [59]. The right anterior insula cortex is as an integration hub for 
autonomic, immune, hormonal, and cardiovascular systems creating a ‘metacognitive map’ of active 
processes such as pain, touch, and temperature, and subjective and emotional feelings [60, 61]. The 
left anterior insular region and the fronto-parietal region contributes to a sense of ‘body ownership’ 
and the temporo-parietal regions to a sense of peripersonal space [62]. These regions are 




interconnected with the anterior cingulate cortex forming an emotional-motivational appraisal 
system associated with pain [63]. There is a shift of activity from the posterior to anterior insula with 
the development of persistent pain reflecting the transition from nociception to emotional 
responses associated with pain [64].  
 
Evidence also suggests that chronic pain impairs resting state activity in the brain by disrupting 
processing in the default mode network contributing to intrusive cognition and a breakdown of the 
normal self [65-67]. Mindfulness training alleviates chronic pain and improves quality of life by 
developing interoceptive attention to bodily sensations [68]. Psychedelic agents act at regions 
modulated during mindfulness including the medial prefrontal cortex, posterior cingulate cortex and 
posterior insula of the default mode network [69-71]. Evidence that 5-HT2A agonists inhibit activity in 
the default mode network and connector hubs, such as the thalamus and anterior cingulate cortex 
[16], may provide opportunities to influence activity in brain regions implicated in chronic pain. 
 
5-HT Receptor Binding, Pain and its Modulation 
Psychedelics have complex receptor interactions with the serotonergic, dopaminergic, and 
glutamatergic systems [51, 72]. Lysergic acid diethylamide and psilocybin principally mediate effects 
through activation of 5-HT2A and 5-HT2C receptors in the central nervous system [73]. These 
receptors are involved in peripheral and centrally mediated pain processes and in the regulation of 
mood, anxiety, and cognition. 5-HT2A and 5-HT7 receptors are involved in anti-nociceptive actions of 
the rostral ventromedial medulla of the descending pain inhibitory pathways that inhibit onward 
transmission of nociceptive information in the spinal cord (i.e. by ‘closing the pain gate’)[74]. 
Injection of 5-HT into the spinal cord region has anti-nociceptive effects [75]. Drugs that elevate 5-HT 
levels such as selective serotonin reuptake inhibitors (SSRIs), are indicated for neuropathic pain, 
musculoskeletal pain and fibromyalgia [76, 77], although evidence about clinical efficacy is 
inconclusive [78-80]. However, the role of 5-HT in pain processing is bi-directional [81]. For example, 
persistent pain arising from nerve injury is driven by augmented 5-HT circuitry in the central nervous 
system and pro-nociceptive actions of 5-HT on central 5-HT3 receptors. In the periphery, 5-HT2A 
agonists are pro-nociceptive increasing the effect PGE2 and noradrenaline [82] and producing 
thermal hyperalgesia [83]. 
 
Evidence from in-vivo electrophysiology in rats suggests that LSD has partial agonist actions at 5-HT2A 
receptors and full antagonistic action at 5-HT1A in the dorsal raphe, a structure known to be involved 




in actions of descending pain inhibitory processes [72]. Descending pain inhibitory pathways are rich 
in opioid receptors and activation of mu opioid receptors generates analgesia by inhibiting onward 
transmission of nociceptive information at various levels in the central nervous system. Mu opioid 
receptors are distributed in mesolimbic regions including the ventral tegmental area and striatum 
and these classical dopaminergic regions are associated the sense of reward associated with natural 
behaviors and drugs [84-86]. At higher doses, LSD modulates activity in the ventral tegmental area of 
the mesolimbic reward system through activation of D2, TAAR1 and 5-HT2A. Mesolimbic circuits 
modulate nociceptive processes in animal models of neuropathic pain [87] and generate the sense 
of reward associated with relief of pain [88-90]. However, the reciprocal relationship between 5-HT, 
opioids, dopamine and noradrenaline is complex with wide spread interconnectivity and 
bidirectional pro-nociceptive and anti-nociceptive effects [74]. At present, there is an absence of 
studies investigating the how psychedelics may influence processing of nociceptive information in 
these brain regions. 
 
Lysergic acid diethylamide, Psilocybin and Inflammation 
Recently, Nichols et al.  [10, 73] have suggested that psychedelic substances may have potential as 
therapeutic agents for inflammatory diseases including rheumatoid arthritis via peripheral actions at 
5-HT2A receptors. Psychedelic substances instigate signal transduction processes via activation of 5-
HT2A receptors at peripheral sites resulting in activation of protein-kinase C, which in turn regulates 
signal transduction processes associated with the transcription of pro-inflammatory genes mediated 
via tissue necrosis factor. Tissue necrosis factor is implicated in a wide variety of inﬂammatory, 
infectious and malignant conditions and anti-TNF antibodies have been used to manage 
inﬂammatory conditions including rheumatoid arthritis [91]. There is a need for further research.  
 
Clinical Research on Lysergic acid diethylamide and Psilocybin to Alleviate Pain 
There is a paucity of clinical trials to assess whether LSD or psilocybin have analgesic properties. 
Evidence to date is from small-scale case series in patients with terminal illness, migraine or cluster 
headache (Figure 1). One of the first documented human clinical trials assessing the analgesic effects 
of LSD was in 1964 when Kast and Collins [92] administered a single-dose of dihydromorphone HCl 
(2mg) and pethidine (meperidine HCl 100mg) in a randomised sequence with a six-hour interval to 
50 patients with pain related to cancer or gangrene of hands or feet. Patients who were still 
experiencing pain six hours after the administration of the second analgesic drug were administered 
a single dose of LSD (100 μg p.o.). Data presented in the report were difficult to interpret although it 




appeared that 48.9% of the patients receiving LSD experienced no pain for at least 19 hours post 
dose. Kast and Collins concluded that LSD provided a longer and more effective analgesic action than 
pethidine and dihydromorphone, and that many patients were able to discuss their death freely and 
displayed “a peculiar disregard for the gravity of their situation” p291 [92]. In 1967, Kast [93] 
reported that LSD (100 μg p.o.) had analgesic actions in a series of 128 terminally ill patients, 
commencing at two to three hours after administration and lasting for 12 hours. In 1969, Pahnke et 
al. [94] reported the findings of a case series of 22 patients that had terminal metastatic cancer with 
depression and received LSD psychotherapy. Pahnke et al. claimed that LSD psychotherapy improved 
pain, mood, anxiety and fear of death, with no adverse effects some but not all patients, although 
there was no quantitative nor qualitative data provided in the report. In 1973, Grof et al. [95] 
administered LSD assisted psychotherapy for 31 patients with pain, anxiety and depression 
associated with terminal metastatic malignancies and found significant improvements in pain 
severity, pre-occupation with pain and physical suffering, anxiety, depression and fear of death.   
 
[Insert Figure 1 here – Timeline of Studies Utilising Psychedelics as Analgesics] 





Lysergic acid diethylamide and psilocybin derivatives are structurally related to drugs used to 
manage migraine and have been used as a potential prophylactic treatment for migraines and 
vascular headaches since the 1960s [96, 97](for review see [98]). At present, there is an absence of 
controlled clinical trial evidence to judge clinical efficacy, although internet surveys have found that 
patients report benefits from using LSD and psilocybin for treatment resistant cluster headaches. 
Sewell et al. [99] interviewed 53 patients that were self-medicating at LSD and/or psilocybin-
containing mushrooms and found that episodes of cluster headache ceased (n = 7/8 LSD users, n = 
25/48 psilocybin users) or the duration of remission was extended (n = 4/5 LSD users, 18/19 
psilocybin users) following treatment. Sewell et al. concluded that LSD or psilocybin were better 
than standard drugs at instigating and extending remission. In 2015, Schindler et al., [100] surveyed 
496 people recruited from cluster headache websites and headache clinics who reported that 
variety of psychedelic drugs (psilocybin, lysergic acid diethylamide, and lysergic acid amide) were 
beneficial and often more efficacious than conventional medication, even at non-hallucinogenic 
doses. Karst et al. [101] conducted an open label, non-randomized case series of five patients with 
treatment resistant cluster headache who received a non-hallucinogenic analogue of LSD (i.e. 2-
bromo-lysergic acid diethylamide (BOL-148)) that had been synthesised to combat the potentially 
undesirable hallucinogenic properties of LSD. Three single doses of BOL-148 given over 10 days 
reduced the frequency and intensity of cluster headache with remission extending for many months 
or longer.  BOL-148 binds to 5-HT2A receptors but has lower efficacy than LSD generating less 
inhibitory activity of neurons in brain structures [102]. Karst et al. [101] suggested that the 
alleviation of cluster headache by BOL-148 (and by inference LSD and psilocybin) was associated 
with 5-HT receptor-mediated vasoconstriction rather than psychedelic effects mediated via 5-HT1A 
and 5-HT2A receptors.  Interestingly, a double-blind study by Johnson et al. [103] demonstrated that 
psilocybin causes transient headache in a dose-dependent manner in healthy individuals, although 
the duration of headaches were always less than 24 hours and the severity of headaches was not 
disabling. 
 
In 1977, Fanciullacci et al. [104] reported that five out of seven patients with phantom limp pain who 
were administered sub-hallucinogenic doses of LSD (25 μg p.o./ day for one week followed by 50 μg 
p.o./ day for a further two further weeks) reported improvement in pain and reductions in analgesic 
consumption. We have been unable to find any other reports of the use of LSD or psilocybin for pain. 
 




Conclusion and the Future 
Chronic pain and its management pose a global healthcare problem. With current mainstay drugs, 
such as opioids, proving problematic there is a need to explore novel pharmacological therapies. Our 
review suggests there is insufficient evidence to determine whether LSD and psilocybin may be of 
benefit for patients with persistent pain in the presence and absence of neuropsychiatric ailments. 
Our review offers indirect evidence that psychedelic drugs such as LSD and psilocybin may interact 
with endogenous systems in the brainstem and spinal cord that utilise 5-HT such as those involved 
with inhibition of onward transmission of nociceptive information. Lysergic acid diethylamide and 
psilocybin influence activity in the same regions of the cerebrum associated with pain as an 
‘embodied’ and ‘embedded’ perceptual experience, including emotional, motivational, and cognitive 
appraisal systems. Lysergic acid diethylamide and psilocybin interact with brain regions associated 
with the default mode network that generates a resting conscious state of awareness. Pain disrupts 
activity in the default mode network so it seems plausible that LSD and psilocybin may alleviate 
intrusive cognition and the breakdown of normal-self associated with persistent pain.  
 
The role of a psychedelic experiences in analgesic outcome is unknown although anti-depressant and 
anxiolytic effects have been shown to occur at sub-hallucinogenic doses. The potential anti-
inflammatory properties of LSD and psilocybin may also prove beneficial. There is an absence of 
clinical trials on the clinical efficacy of LSD and psilocybin for pain, although evidence from 
uncontrolled case series is promising for alleviating pain, anxiety and depression in terminal illness, 
migraine and cluster headache. Lysergic acid diethylamide and psilocybin appear to be generally safe 
if administered under the supervision of a health care professional and do not appear to lead to 
physiological dependence. Our review suggests a need to assess the utility of derivatives of LSD and 
psilocybin for patients with persistent pain, especially associated with terminal illness, in the 
presence and absence of neuropsychiatric ailments.  
 
Future Perspective 
Psychedelics appear to have potential to alter management in multiple areas of medicine, yet 
progress in this field has been dormant due in part to restrictions on the use of the agents in 
research and clinical practice. The medical community remains reluctant to explore the clinical utility 
of psychedelics due to safety and abuse concerns. Evidence suggests that these substances are safe 
and non-addictive for selected patients if administered under carefully controlled clinical conditions. 
Psychiatry, addiction, pain and end-of-life care are notoriously challenging to effectively treat and 




carry costly socioeconomic burdens. Psilocybin and LSD are relatively inexpensive to produce and 
cost would decline as demand for therapeutic use increases.  Presently, evidence for the use of 
psychedelics in pain management and end-of-life care is limited to pilot studies and uncontrolled 
case series and there is a need for methodologically robust randomised controlled clinical trials to 
evaluate the effectiveness.  
 
Our review has revealed an absence of studies from basic sciences assessing the analgesic properties 
of psychedelic agents using animal models of nociception that record electrophysiological and 
behavioural outcomes as proxy measures of pain. Systematic investigation of the direct and indirect 
actions of psychedelics on nociceptive processing at hallucinogenic and sub-hallucinogen doses 
would inform the potential of these agents for use in the management of pain in a variety of 
circumstances including at the end-of-life and medical conditions such as neuropathic pain and 
potentially complex acute pain.  
 
Practice Points 
 Worldwide interest in the potential therapeutic value of psychedelics is increasing in many areas 
of science and healthcare. 
 Evidence tentatively suggests benefits in addiction, treatment-resistant depression, terminal-
illness related anxiety, obsessive-compulsive disorder, cluster headaches and pain. 
 Psychedelics may alleviate pain indirectly through the action a psychedelic experience has on an 
individual’s metacognitive interpretation of the pain.  
 Psychedelics may act on the brain modulate similar pathways to mindfulness. 
 Psychedelics may alleviate pain directly through 5-HT2A receptor binding at the rostral 
ventromedial medulla with enhancement of descending pain inhibitory pathways.  
 There have been no trials assessing the effectiveness of psychedelics in the management of 
acute or chronic pain since 1977. 
 There are reports that self-medication with psychedelics is superior to current medications in 
the treatment of cluster headaches and a small case series demonstrated 2-bromo-lysergic acid 
diethylamide (BOL) improved cluster headache symptoms and frequency of attacks. 
 Small studies without controls suggest potential benefit for malignant and neuropathic pain.   
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